Cryoport, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cryoport, Inc. (Nasdaq: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry, focusing on biopharmaceuticals, pharmaceuticals, animal health, and human reproductive medicine, with primary emphasis on the cell and gene therapy sector; the company offers cryogenic systems, bio-logistics, bio-storage, bio-processing, advanced packaging including Cryoport Express dry vapor shippers, Cryoport ELITE -80°C shippers, C3 refrigerated and controlled room temperature solutions, IntegriCell cryopreservation services, Cryoportal logistics management platform, Smartpak II condition monitoring, consulting for custom packaging, and biostorage services such as controlled temperature storage, fulfillment, kit production, and GMP raw materials management. Founded in 1999 and headquartered in Brentwood, Tennessee, Cryoport operates through its family of companies including Cryoport Systems, MVE Biological Solutions, and CRYOGENE, with over 50 strategic locations across the Americas, EMEA, and APAC. The company serves clinical trials, commercial therapies, and regenerative medicine markets globally, supporting more than 650 active clinical trials and 10 commercial products. In June 2025, Cryoport completed the divestiture of its CRYOPDP specialty courier business to DHL Group for approximately $200 million in cash proceeds and established a strategic partnership with DHL to enhance market presence in APAC and EMEA while refocusing on core life science services; recent expansions include a new 55,000-square-foot Global Supply Chain Center in Louvres, France near Paris opened in October 2025 for 24/7 logistics, biostorage, and QP services, a 21,000-square-foot facility in Houston, Texas, and product launches such as MVE Biological Solutions' next-generation vapor shippers and real-time condition monitoring systems for cryogenic dewars.
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
Cryoport Reports First Quarter 2026 Financial Results
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven
CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
EXCLUSIVE: New Fusion 800 Launch Signals Cryoport's Ambition To Modernize Cryogenic Storage
CryoPort (NASDAQ:CYRX) vs. Royal Mail (OTCMKTS:ROYMY) Head-To-Head Contrast
CryoPort, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
CryoPort, Inc. $CYRX Shares Bought by Assenagon Asset Management S.A.
Cryoport: Picks And Shovels For The Gene Therapy Boom
CryoPort, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Analysts
Acadian Asset Management LLC Purchases 69,147 Shares of CryoPort, Inc. $CYRX
Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”
Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript